Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales
NegativeFinancial Markets

Novo Nordisk has revised its outlook for the fourth time this year due to disappointing sales of its popular weight-loss drugs, Wegovy and Ozempic. This is significant as it highlights the intense competition in the obesity medication market, particularly from Eli Lilly, which is gaining ground. The company's struggles could impact investor confidence and market dynamics, making it a crucial development to watch in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System










